



KNOPP NEUROSCIENCES is a drug discovery and development company focused on delivering breakthrough treatments in neurological disorders through innovation, experience and partnership. Knopp’s lead compound, KNS-760704 (dexpramipexole), is currently in late-stage clinical development for amyotrophic lateral sclerosis, with additional indications under investigation.
Knopp has aligned with leading collaborators in drug discovery and development. We have partnered the KNS-760704 development program for ALS with Biogen Idec, a global leader in the development and commercialization of neurology products. Our discovery research, preclinical development, and manufacturing and formulation activities are supported by world-class organizations whose scientists and physicians act as extensions of the Knopp team.
Knopp employs innovative approaches to persistent problems in drug discovery and development. We direct our discovery research towards understanding mechanisms of neuronal death associated with the dysfunction of mitochondria, the energy powerhouses of every cell. Our scientists and discovery partners drive advances in electrophysiology, molecular biology, proteomics, process chemistry, and drug delivery techniques. Our clinical leaders and development partners drive advances in safety and medical outcomes.
The Knopp team combines executive experience, regulatory know-how, and entrepreneurial agility. Former senior executives from Bristol-Myers Squibb, emerging biotech companies, and leading Contract Research Organizations are joined here by veterans of technology investing and venture creation.
-- Biogen Idec expects to initiate Phase 3 program in the first half of 2011 -- Equity investment and potential license payments ......
TORONTO, April 16, 2010--In an invited presentation today before the annual meeting of the American Academy of Neurology, Knopp ......
San Diego, CA, USA - November 13 -17, 2010 http://www.sfn.org...
Orlando, Florida, USA - December 11-13, 2010 http://www.mndassociation.org...